Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease

•Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer.•A clinically significant dose of olaprib is able to penetrate the leptomeninges.•Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to olaparib.

Bibliographic Details
Main Authors: Bangham, Madeleine, Goldstein, Robert, Walton, Henry, Ledermann, Jonathan A
Format: Online
Language:English
Published: Elsevier 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081421/
id pubmed-5081421
recordtype oai_dc
spelling pubmed-50814212016-11-04 Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease Bangham, Madeleine Goldstein, Robert Walton, Henry Ledermann, Jonathan A Case Report •Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer.•A clinically significant dose of olaprib is able to penetrate the leptomeninges.•Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to olaparib. Elsevier 2016-10-19 /pmc/articles/PMC5081421/ /pubmed/27819019 http://dx.doi.org/10.1016/j.gore.2016.10.004 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Bangham, Madeleine
Goldstein, Robert
Walton, Henry
Ledermann, Jonathan A
spellingShingle Bangham, Madeleine
Goldstein, Robert
Walton, Henry
Ledermann, Jonathan A
Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
author_facet Bangham, Madeleine
Goldstein, Robert
Walton, Henry
Ledermann, Jonathan A
author_sort Bangham, Madeleine
title Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
title_short Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
title_full Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
title_fullStr Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
title_full_unstemmed Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
title_sort olaparib treatment for brca-mutant ovarian cancer with leptomeningeal disease
description •Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer.•A clinically significant dose of olaprib is able to penetrate the leptomeninges.•Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to olaparib.
publisher Elsevier
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081421/
_version_ 1613699358220353536

Similar Items